This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BOLD 113
- Sponsors Eisai Inc
- 31 Oct 2016 Planned number of patients changed from 20 to 23.
- 15 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2016.
- 07 Jun 2016 Results (n=23) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology